Last reviewed · How we verify
YAZ (SH T00186D)
YAZ is a combination oral contraceptive that contains drospirenone and ethinyl estradiol, which work to prevent ovulation and pregnancy.
YAZ is a combination oral contraceptive that contains drospirenone and ethinyl estradiol, which work to prevent ovulation and pregnancy. Used for Prevention of pregnancy, Treatment of moderate acne in women of childbearing potential, Treatment of hirsutism in women of childbearing potential.
At a glance
| Generic name | YAZ (SH T00186D) |
|---|---|
| Sponsor | Bayer |
| Drug class | estrogen-progestin combination |
| Modality | Small molecule |
| Therapeutic area | Women's Health |
| Phase | Phase 3 |
Mechanism of action
Drospirenone is a progestin that has anti-androgenic properties, which helps to prevent ovulation and also has some anti-inflammatory effects. Ethinyl estradiol is an estrogen that helps to regulate the menstrual cycle and prevent pregnancy.
Approved indications
- Prevention of pregnancy
- Treatment of moderate acne in women of childbearing potential
- Treatment of hirsutism in women of childbearing potential
- Treatment of symptoms of endometriosis
- Treatment of symptoms of polycystic ovary syndrome (PCOS)
Common side effects
- Nausea
- Breast tenderness
- Headache
- Mood changes
- Vaginal bleeding irregularities
Key clinical trials
- Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles (PHASE3)
- SH T00186 in the Treatment of Primary Dysmenorrhea (PHASE3)
- Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ (PHASE3)
- Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: YAZ and YAZ + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and YAZ + Levomefolate Calcium (Metafolin) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YAZ (SH T00186D) CI brief — competitive landscape report
- YAZ (SH T00186D) updates RSS · CI watch RSS
- Bayer portfolio CI